
MBM-55
CAS No. 2083622-09-5
MBM-55( —— )
Catalog No. M26289 CAS No. 2083622-09-5
MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 357 | Get Quote |
![]() ![]() |
10MG | 530 | Get Quote |
![]() ![]() |
25MG | 851 | Get Quote |
![]() ![]() |
50MG | 1152 | Get Quote |
![]() ![]() |
100MG | 1557 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameMBM-55
-
NoteResearch use only, not for human use.
-
Brief DescriptionMBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis.
-
DescriptionMBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis.(In Vitro):MBM-55 (0.5-1 μM; 24 hours) induces G2/M phase arrest and accumulation of cells with >4N content in HCT-116 cells. MBM-55 (0.5-1 μM; 24 hours) causes cell apoptosis in a concentration-dependent manner in HCT-116 cells.MBM-55 inhibits MGC-803, HCT-116, Bel-7402 cells proliferation with IC50s of 0.53, 0.84, 7.13 μM, respectively.(In Vivo):In female BALB/c nu/nu mice bearing HCT-116 xenografts, MBM-55 (20 mg/kg; i.p.) exhibits good antitumor activity and a well-tolerated dose schedule. MBM-55 (1.0 mg/kg; i.v.) shows the CL, Vss, T1/2, AUC0-t, and AUC0-∞ values of 33.3 mL/min/kg, 2.53 L/kg, 1.72 hours, 495 ng/h/mL and 507 ng/h/mL, respectively.
-
In VitroCell Cycle Analysis Cell Line:HCT-116 cells Concentration:0.5, 1 μM Incubation Time:24 hours Result:Induced G2/M phase arrest and accumulation of cells with >4N content.Apoptosis Analysis Cell Line:HCT-116 cells Concentration:0.5, 1 μM Incubation Time:24 hours Result:Caused cell apoptosis in a concentration-dependent manner.
-
In VivoAnimal Model:Female BALB/c nu/nu mice (5-6 weeks, bearing HCT-116 xenografts) Dosage:20 mg/kg Administration:Intraperitoneal injection; twice a day for 21 days Result:Significantly suppressed tumor growth.Animal Model:Male Sprague Dawley (SD) rats Dosage:1.0 mg/kg Administration:IV injection (Pharmacokinetic Analysis)Result:The CL, Vss, T1/2, AUC0-t, and AUC0-∞ values were 33.3 mL/min/kg, 2.53 L/kg, 1.72 hours, 495 ng/h/mL and 507 ng/h/mL, respectively.
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetGSK-3
-
RecptorAChE
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2083622-09-5
-
Formula Weight498.562
-
Molecular FormulaC28H27FN6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (250.73 mM)
-
SMILESCN(C)CCn1cc(cn1)-c1ccn2c(cnc2c1)-c1ccc(C(N)=O)c(OCc2cccc(F)c2)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Wang Y, Dong Y, et al. Acephate interferes with androgen synthesis in rat immature Leydig cells. Chemosphere. 2020 Apr;245:125597.
molnova catalog



related products
-
BRD1172
BRD1172 is a highly selective, potent, reversible, ATP-competitive GSK3 inhibitor with IC50 of 3 nM/10 nM for GSK3α/GSK3β, respectively.
-
Vesnarinone
Vesnarinone (INN) is a mixed phosphodiesterase 3 inhibitor and ion-channel modifier that has modest, dose-dependent, positive inotropic activity.
-
Tideglusib
Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay.